HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Peter K. Smith Michel Carrier John C. Chen Axel Haverich Jerrold H. Levy Philippe Menasché Stanton K. Shernan Peter X. Adams Edward Verrier Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, P. K. Articles by Verrier, E. Search for Related Content PubMed PubMed Citation Articles by Smith, P. K. Articles by Verrier, E. Related Collections Coronary disease

Ann Thorac Surg 2006;82:781-789
© 2006 The Society of Thoracic Surgeons

---

Original article: Cardiovascular

Effect of Pexelizumab in Coronary Artery Bypass Graft Surgery With Extended Aortic Cross-Clamp Time

^a Duke University Medical Center, Durham, North Carolina
^b Montréal Heart Institute, Montréal, Quebec, Canada
^c University of Hawaii, Honolulu, Hawaii
^d Hannover Medical School, Hannover, Germany
^e Emory University Hospital, Atlanta, Georgia
^f Hôpital Européen Georges Pompidou, Paris, France
^g Brigham and Women's Hospital, Boston, Massachusetts
^h University Hospital Gasthuisberg, Leuven, Belgium
ⁱ Alexion Pharmaceuticals, Cheshire, Connecticut
^j Procter & Gamble Pharmaceuticals, Mason, Ohio
^k University of Washington, Seattle, Washington

Accepted for publication February 2, 2006.

^_* Address correspondence to Dr Smith, Duke University Medical Center, PO Box 3442, Durham, NC 27710 (Email: smith058{at}mc.duke.edu).

Presented at the Fifty-second Annual Meeting of the Southern Thoracic Surgical Association, Orlando, FL, Nov 10–12, 2005.

BACKGROUND: Prolonged cross-clamp time during cardiac surgery increases the risk of postoperative mortality and myocardial injury. This subanalysis from the pexelizumab for reduction of infarction and mortality in coronary artery bypass grafting surgery (PRIMO-CABG) trial, a phase III double-blind, placebo-controlled study of 3,099 patients undergoing on-pump coronary artery bypass graft surgery with or without valve surgery, assessed the impact of pexelizumab, an investigational C5 complement inhibitor, on postoperative outcomes after prolonged aortic cross-clamp time.

METHODS: The composite endpoint of death or myocardial infarction through postoperative day 30 and death alone through days 30, 90, and 180 were examined in subpopulations of patients across different cross-clamp times.

RESULTS: After prolonged cross-clamping (90 minutes), death, or myocardial infarction through day 30 and death through days 30, 90, and 180 were significantly increased in the intent-to-treat population and were even higher in patients with two or more prespecified risk factors, compared with all patients cross-clamped less than 90 minutes. Pexelizumab significantly reduced the incidence of death or myocardial infarction through day 30, and significantly reduced the incidence of mortality through day 180, in patients with two or more risk factors that required prolonged cross-clamp time. Pexelizumab also significantly reduced perioperative myocardial injury in all patients requiring prolonged cross-clamp time.

CONCLUSIONS: In this retrospective, subgroup analysis, pexelizumab reduced postoperative morbidity and myocardial injury in patients with multiple risk factors who underwent prolonged cross-clamp time during coronary artery bypass surgery. The clinical benefit of pexelizumab may be related to the effect of complement inhibition in the presence of potential ischemic-reperfusion injury associated with prolonged aortic cross-clamp time.

This article has been cited by other articles:

				H. L. Lazar, T. Keilani, C. A. Fitzgerald, O. M. Shapira, C. T. Hunter, R. J. Shemin, H. C. Marsh Jr, U. S. Ryan, and the TP10 Cardiac Surgery Study Group Beneficial Effects of Complement Inhibition With Soluble Complement Receptor 1 (TP10) During Cardiac Surgery: Is There a Gender Difference? Circulation, September 11, 2007; 116(11_suppl): I-83 - I-88. [Abstract] [Full Text] [PDF]